Checked.be
Active
BE 0450.359.815Private limited company
PROTEOMIS
Sint-Michielslaan 119 ·1040 Etterbeek, Belgium· 33 yrs active
Sector: Medical imaging and medical laboratories
(86910)
Conclusion
PROTEOMIS has been active since 1993 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €448k and a net result of €-688. Equity remains stable across the filed fiscal years (±1.2% per year). Its solvency ranks better than 55% of 2251 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 5 annual accounts.
Key figures
| Equity | €448k |
| Net result | €-688 |
| Staff (FTE) | 3 |
| Better than sector | 55% |
Financial profile
63
/ 100
Strong profile, led by solvency.
All 5 axes are computed from data Checked has read.
Health
65
Profitability
0
Solvency
100
Growth
52
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 1993, 33 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
65
/ 100
Healthy
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€30k
estimate, not credit advice
Score history
86
2021
78
2022
94
2023
83
2024
65
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 2.56 (≥ 1.5)
+10
Quick ratio
Quick ratio 2.56 (≥ 1.0)
+5
Leverage
Debt/equity 0.53 (< 1.0)
+10
Profitability
Negatieve ROE 0%
-10
Interest coverage
Interest coverage 2.6×
+3
Profit trend
Net profit down YoY
-3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 31-08-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
stable
Equity: stable across 5 fiscal years (±1.2%/year).
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 65.5% | 59.8% | |
| Net result | €-688 | €121k | |
| Equity | €448k | €396k | |
| Gross operating margin | €297k | €301k | |
| Staff costs | €230k | €111k |
€57k
-48.4%
21-25
€-688
-
21-25
€21k
-78.7%
21-25
€685k
-7.3%
21-25
€448k
-0.2%
21-25
€370k
-12.7%
21-25
3
0.0%
21-25
€230k
+11.3%
21-25
€14k
-
21-25
€8k
-
21-25
€236k
-18.3%
21-25
€236k
+10.2%
21-25
€75k
-16.9%
21-25
2.56
-13.8%
21-25
2.56
-13.8%
21-25
65.5%
+7.7%
21-25
0.53
-18.2%
21-25
-0.2%
-
21-25
-0.1%
-
21-25
2.56
-62.7%
21-25
Figures by fiscal year and ratios
Change versus the prior fiscal year, coloured by direction (green = favourable).
| Fiscal year | 2025 Δ | 2024 Δ | 2023 Δ | 2022 Δ | 2021 Δ |
|---|---|---|---|---|---|
| Deposit | abbreviated schema | full schema | full schema | full schema | full schema |
| Revenue | - | - | - | - | - |
| EBITDA | -48.4% | -4.3% | - | - | - |
| Net profit | - | -37.4% | +504.7% | -87.4% | - |
| Cash flow | -78.7% | +16.4% | - | - | - |
| Staff costs | +11.3% | -2.9% | +5.9% | -11.8% | - |
| Income taxes | - | - | +305.8% | -73.3% | - |
| Dividends | - | - | - | - | - |
| Total assets | -7.3% | -6.0% | +21.6% | -6.5% | - |
| Equity | -0.2% | -0.6% | +4.6% | +0.8% | - |
| Debt | -18.3% | -13.2% | +56.1% | -18.3% | - |
| of which ≤ 1y | +10.2% | -11.9% | +13.8% | -18.3% | - |
| of which > 1y | - | -16.9% | - | - | - |
| Working capital | -12.7% | +27.7% | -21.0% | +0.8% | - |
| Employees (FTE) | - | - | - | 0.0% | - |
Note: these years are not on the same basis. The filed schemas differ (abbreviated schema, full schema), so the columns are not directly comparable.
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 2.56 | 2.97 | 2.36 | 2.96 | 2.59 |
| Quick ratio | 2.56 | 2.97 | 2.36 | 2.96 | 2.59 |
| Working capital ratio | 54.0% | 57.3% | 42.2% | 65.0% | 60.3% |
| Solvency | 65.5% | 60.8% | 57.5% | 66.9% | 62.1% |
| Debt / equity | 0.53 | 0.64 | 0.74 | 0.49 | 0.61 |
| Long-term debt ratio | - | 0.17 | 0.20 | - | - |
| Interest coverage | 2.56 | 6.87 | 6.76 | - | 3.99 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | -0.1% | 1.7% | 2.5% | 0.5% | 3.8% |
| ROE | -0.2% | 2.7% | 4.4% | 0.8% | 6.0% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (24 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €685k | €738k | €785k | €646k | €690k |
| Fixed assets | 21/28 | €78k | €101k | €210k | €12k | €12k |
| Intangible fixed assets | 21 | €66k | €88k | €198k | - | - |
| Financial fixed assets | 28 | €12k | €12k | €12k | €12k | €12k |
| Current assets | 29/58 | €606k | €638k | €575k | €634k | €678k |
| Amounts receivable within one year | 40/41 | €121k | €111k | €114k | €192k | €178k |
| Cash & bank | 54/58 | €486k | €527k | €461k | €442k | €500k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €685k | €738k | €785k | €646k | €690k |
| Equity | 10/15 | €448k | €449k | €452k | €432k | €429k |
| Contributions / capital | 10/11 | €6k | €6k | €6k | €6k | €6k |
| Reserves | 13 | €90k | €90k | €93k | €73k | €73k |
| Accumulated profits (losses) | 14 | €352k | €353k | €353k | €353k | €350k |
| Amounts payable | 17/49 | €236k | €289k | €334k | €214k | €262k |
| Amounts payable after one year | 17 | - | €75k | €90k | - | - |
| Amounts payable within one year | 42/48 | €236k | €214k | €243k | €214k | €262k |
| Trade debts payable within one year | 44 | €58k | €91k | €143k | €141k | €194k |
| Income statement | ||||||
| Gross operating margin | 9900 | €297k | €327k | €352k | €298k | €356k |
| Operating result | 9901 | €34k | €21k | €48k | €19k | €50k |
| Financial income | 75 | €439 | €297 | - | - | €166 |
| Financial charges | 65 | €22k | €16k | €17k | €13k | €13k |
| Result before taxes | 9903 | €13k | €6k | €31k | €6k | €36k |
| Income taxes | 67/77 | €14k | €-7k | €11k | €3k | €10k |
| Net result for the period | 9904 | €-688 | €12k | €20k | €3k | €26k |
| Result to be appropriated | 9905 | €-688 | €12k | €20k | €3k | €26k |
Legal Structure
| NACE primary | Medical imaging and medical laboratories(86910) |
| Legal form | Private limited company(610) |
| Incorporation | 22-06-1993 |
| Status | Active |
| Postal code | 1040 |
Establishment units
PROTEOMIS
since 19932.063.084.783
Real-estate footprint
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21362B0294/00T004 | Brussels | 355 m² | 1 · 188 m² | 20.4 m · 5 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
23-04
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 266 days late
23-04
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 631 days late
2025
31-12
Financial
Weakest financial yearnet €-688 ▼106%
Net result drops to €-688, the lowest in the series.
2023
30-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 30 days late
2022
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 31 days late
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 31 days late
2020
29-10
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 90 days late
2019
25-11
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 117 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 31 days late
2017
29-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 29 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
85141Human health activities86901Medical imaging and medical laboratories86910Business and other management consultancy70200Business consulting70220Office administrative, office support and other business support activities82910
Names & trade names
| Legal nameFR | PROTEOMIS |
Similar companies
CABINET DU DR ISABELLE CAPRON
BE 0863.588.030 · Schaarbeek
IMAMED DOCTEUR ALLART
BE 0505.850.248 · Boussu
Docteur André VANESCOTE Biologie Clinique
BE 0837.326.764 · Geer
Maparo
BE 0811.350.560 · Dilbeek
DE WULF Médical
BE 0821.027.497 · Namur